Advanced Oncotherapy (AVO) – Major Shareholder increases stake

Home » Advanced Oncotherapy (AVO) » Advanced Oncotherapy (AVO) – Major Shareholder increases stake

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise
price

Expiration
date ^xvii

Exercise/
Conversion
period ^xviii

Number of voting
rights instrument
refers to

% of voting rights^{xix, xx}

NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ

Advanced Oncotherapy plc

2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights		X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):

3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	AB Segulah
4. Full name of shareholder(s) (if different from 3.): ^iv	HSBC Global Custody Nominee (UK)
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	20 March 2017
6. Date on which issuer notified:	20 March 2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	5%

8. Notified details:
A: Voting rights attached to shares ^{viii, ix}
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights ^x
			Direct	Direct ^xi	Indirect^xii	Direct	Indirect
Ordinary Shares GBP 0.25 GB00BD6SX109	3,505,451	3,505,451	3,680,451	3,680,451		5.06%

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date ^xiii	Exercise/ Conversion Period ^xiv	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: ^xxi

The 3,680,451 shares are held by HSBC Global Custody Nominee (UK) under direct control of AB Segulah.

Proxy Voting:
10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

Tags: ab segulah, advanced oncotherapy, advanced oncotherapy major shareholder list, avo, david navas